TRDA
Entrada Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$493.80M
P/E Ratio
—
EPS
$-3.47
Beta
-0.15
52W High
$14.49
52W Low
$4.93
50-Day MA
$12.64
200-Day MA
$9.09
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
3333.33
PEG Ratio
—
About Entrada Therapeutics Inc
Entrada Therapeutics Inc. (TRDA) is an innovative biotechnology company dedicated to developing groundbreaking therapies to address severe diseases with significant unmet medical needs. Utilizing its proprietary Therapeutics for RNA Delivery (TRADA) platform, Entrada targets RNA and protein dysfunctions linked to conditions such as muscular dystrophies and genetic disorders. The firm boasts a strong clinical pipeline and a commitment to scientific excellence, positioning itself well for impactful advancements in patient care. Led by an experienced team, Entrada is poised to make significant contributions to the biopharmaceutical industry through its cutting-edge therapeutic solutions.
Fundamentals
| Revenue (TTM) | $25.42M |
| Gross Profit (TTM) | $-115.15M |
| EBITDA | $-151.90M |
| Operating Margin | -3103.00% |
| Return on Equity | -39.10% |
| Return on Assets | -21.60% |
| Revenue/Share (TTM) | $0.61 |
| Book Value | $8.50 |
| Price-to-Book | 1.61 |
| Price-to-Sales (TTM) | 19.42 |
| EV/Revenue | 9.8 |
| EV/EBITDA | 1.58 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -96.50% |
| Shares Outstanding | $38.82M |
| Float | $21.72M |
| % Insiders | 12.38% |
| % Institutions | 75.67% |
Historical Volatility
HV 10-Day
48.10%
HV 20-Day
47.16%
HV 30-Day
53.65%
HV 60-Day
60.52%
HV Rank
15.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($21.40 target)
7
BuyData last updated: 5/1/2026